Skip to main content
. 2019 Mar 13;37(13):1120–1129. doi: 10.1200/JCO.18.01731

FIG 4.

FIG 4.

Plot of the proportion of circulating tumor cells (CTCs) that tested positive for androgen receptor splice variant 7 (AR-V7) nuclear protein (red) at (A) baseline and at (B) progression on abiraterone acetate or enzalutamide as a function of the total number of CTCs, including AR-V7–negative CTCs (blue).